2021
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP, investigators N. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology 2021, 22: 1752-1763. PMID: 34793718, DOI: 10.1016/s1470-2045(21)00572-6.Peer-Reviewed Original ResearchConceptsMedian overall survivalMidgut neuroendocrine tumorsTreatment-related serious adverse eventsLong-term safety resultsFinal overall survivalPrespecified final analysisPhase 3 trialProgression-free survivalSerious adverse eventsOverall survivalLu-DOTATATE treatmentAdverse eventsNeuroendocrine tumorsLu-DOTATATESecondary endpointsLast patientMyelodysplastic syndromeSafety resultsInteractive web-based response systemControl groupAdvanced midgut neuroendocrine tumorsFinal overall survival analysisWeb-based response systemFinal analysisNETTER-1 trialRapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors
Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas 2021, 50: 890-894. PMID: 34398071, DOI: 10.1097/mpa.0000000000001841.Peer-Reviewed Original ResearchConceptsPeptide receptor radionuclide therapyProgressive diseaseNeuroendocrine tumorsBiopsy-proven neuroendocrine tumorHigher disease control rateMedian progression-free survivalShorter progression-free intervalStanford Cancer CenterDisease control rateMetastatic neuroendocrine tumorsMonths of therapyProgression-free survivalProgression-free intervalReceptor radionuclide therapyBetter patient selectionLarge patient cohortHigh-grade componentHigher disease gradeLow-grade componentRepeat biopsyMedian timePatient selectionInitial pathologyPredictive factorsCancer Center
2020
Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities
Shaheen S, Moradi F, Gamino G, Kunz PL. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Current Treatment Options In Oncology 2020, 21: 25. PMID: 32172368, DOI: 10.1007/s11864-020-0711-9.Peer-Reviewed Original ResearchConceptsPeptide receptor radionuclide therapySomatostatin analoguesToxicity of PRRTOpinion statementNeuroendocrine tumorsMetastatic neuroendocrine tumorsLandscape of treatmentReceptor radionuclide therapyRecent treatment advancesTreatment of NETsPatient selectionNeuroendocrine tumorsTreatment advancesSomatostatin receptorsMinimal response rateRadionuclide therapyResponse rateHeterogenous groupTherapyTumor cellsBiological hallmarksTumorsTreatmentNETsIndolentNeoplasms
2015
Carcinoid and Neuroendocrine Tumors: Building on Success
Kunz PL. Carcinoid and Neuroendocrine Tumors: Building on Success. Journal Of Clinical Oncology 2015, 33: 1855-1863. PMID: 25918282, DOI: 10.1200/jco.2014.60.2532.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoid TumorCell DifferentiationChemoembolization, TherapeuticChemotherapy, AdjuvantHumansNeoplasm StagingNeuroendocrine TumorsPatient SelectionPrecision MedicinePredictive Value of TestsRadiopharmaceuticalsTreatment Outcome
2013
False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer
Paudel N, Kunz PL, Poultsides GA, Koong AC, Chang DT. False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. Practical Radiation Oncology 2013, 4: 368-371. PMID: 25407856, DOI: 10.1016/j.prro.2013.11.005.Peer-Reviewed Original Research
2011
18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases
Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, Quon A. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nuclear Medicine Communications 2011, 32: 343-347. PMID: 21412178, DOI: 10.1097/mnm.0b013e328344894b.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArea Under CurveBevacizumabColorectal NeoplasmsFemaleFluorine RadioisotopesFluorodeoxyglucose F18FluorouracilHumansMaleMiddle AgedPilot ProjectsPositron-Emission TomographyRadiopharmaceuticalsTomography, Emission-ComputedConceptsPET/CT scanningPositron emission tomography/Emission tomography/CT scanningTomography/Standardized uptake value analysisPilot studyStable tumor sizeMetastatic colorectal adenocarcinomaMetastatic colorectal cancerMetastatic colorectal carcinomaAdministration of bevacizumabPresence of cancerDynamic positron emission tomography/Metastasis sizeInjection of radiotracerColorectal metastasesMetastatic lesionsMetastatic sitesTumor sizeColorectal cancerColorectal adenocarcinomaColorectal carcinomaHistopathological analysisRadiotracer uptake
2010
18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy
Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT. 18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2010, 77: 1420-1425. PMID: 20056345, DOI: 10.1016/j.ijrobp.2009.06.049.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCA-19-9 AntigenDeoxycytidineDisease-Free SurvivalFluorodeoxyglucose F18GemcitabineHumansMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPositron-Emission TomographyRadiopharmaceuticalsRadiosurgeryRadiotherapy DosageRetrospective StudiesConceptsMetabolic tumor burdenStereotactic body radiotherapyPancreas cancer patientsPositron emission tomographyMedian survivalCancer patientsOverall survivalMultivariate analysisHigh metabolic tumor burdenMaximum standardized uptake valueAdvanced pancreas cancerProgression-free survivalGemcitabine-based chemotherapyLength of survivalStandardized uptake valuePET scan parametersProgression-FreeChemotherapy cyclesHigher SUVmaxIndependent predictorsTumor burdenBody radiotherapyPancreas cancerPrognostic valueMedian SUVmax